Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvectis Pharma (NVCT) Gains from Sales and Divestitures (2024 - 2026)

Nuvectis Pharma has reported Gains from Sales and Divestitures over the past 3 years, most recently at $190111.0 for Q1 2026.

  • Quarterly results put Gains from Sales and Divestitures at $190111.0 for Q1 2026, up 94.81% from a year ago — trailing twelve months through Mar 2026 was $190111.0 (up 94.81% YoY), and the annual figure for FY2025 was $205290.0, up 65.02%.
  • Gains from Sales and Divestitures reached $190111.0 in Q1 2026 per NVCT's latest filing, down from $205290.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $205290.0 in Q3 2025 and bottomed at $97590.0 in Q1 2025.
  • Median Gains from Sales and Divestitures over the past 3 years was $156497.0 (2024), compared with a mean of $153749.5.
  • The largest annual shift saw Gains from Sales and Divestitures soared 65.02% in 2025 before it skyrocketed 94.81% in 2026.
  • Over 3 years, Gains from Sales and Divestitures stood at $124404.0 in 2024, then skyrocketed by 65.02% to $205290.0 in 2025, then dropped by 7.39% to $190111.0 in 2026.
  • Business Quant data shows Gains from Sales and Divestitures for NVCT at $190111.0 in Q1 2026, $205290.0 in Q4 2025, and $205290.0 in Q3 2025.